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Technetium-99m human serum albumin (99mTc-HSA) is an importantradiopharmaceuticalrequired in nuclear medicine studies.
However, the risk of transfusion-transmitted infection remains a major safety concern. Autopreparation of serum component
acquired from patient provides a “personal-exclusive” source for radiolabeling. This paper is to evaluate the practicality of on-
site elusion and subsequent radiolabeling eﬃcacy for serum albumin. Results showed that the autologous elute contained more
a l b u m i nf r a c t i o nt h a ns e r u mw i t h o u te x t r a c t i o np r o c e d u r e .G o o dradiochemical purity and stability were demonstrated after
radiolabeling. Biodistribution study showed that labeled albumin accumulated immediately in the lung, liver, and kidney. It was
cleared steadily and excreted in the urine. The biologic half-life was deﬁned, and all samples passed the pyrogenicity and sterility
tests. In conclusion, autoalbumin could be extracted and radiolabeled properly in a nuclear medicine setting. Moreover, the risk
of transfusion-transmitted infection associated with nonautologous,multisource 99mTc-HSA agents can be reduced.
1.Introduction
Technetium-99m-labeled human serum albumin (99mTc-
HSA) is an important radiopharmaceutical commonly used
in nuclear medicalservices. Itis routinelyused in lymphosci-
ntigraphic studies, sentinel lymph node mapping, blood
pool imaging, and protein-losing gastroenteropathy [1–7].
However, preparing and maintaining stocks of 99mTc-HSA
remain a challenge due to a shortage in the supply of com-
mercially available kits and a lack of awareness regarding
unknown transfusion-induced infectious diseases.
HSA is the major protein component of human plasma
and is crucial for maintaining plasma volume and the
osmotic pressure of circulating blood [8]. Plasma-derived
HSA (pHSA) is used clinically to correct circulating plasma
volume and improve colloid osmotic pressure. Nevertheless,
the pHSA supply is limited as it is manufactured from
a fractionation of pooled, donated human plasma. This
nonautologous, multisource approach introduces signiﬁcant
risks of allergic reactions and contamination by blood-
derived pathogens, such as human immunodeﬁciency virus
(HIV), viral hepatitis, and Creutzfeldt-Jakob disease prions
[9, 10]. Since 99mTc-HSA is widely applied to nuclear
medicine techniques, constant and stable sources of albumin
are necessary to sustain these diagnostic procedures.
Serum products created from a single-source or limited
domestic supplies are safer than those obtained from pooled
commercial sources, according to the World Health Organi-
zation (WHO) [11–13]. In our previous study, a protocol
was formulated using a domestic serum product to pre-
pare 99mTc-HSA on site in a nuclear medicine laboratory
[14]. This preparation proved safer than the commercially
supplied pooled serum products, biologically stable, and
clinically eﬀective.
However, the risks of introducing an unknown infec-
tious agent could not be completely eliminated. Therefore,2 Journal of Biomedicine and Biotechnology
a need for a protocol to create a single-source autologous
serum albumin (autoalbumin) still exists. Autologous blood
donation is the safest means by which clinical transfusion
products can be prepared for an individual [15, 16]. In this
article, we describe the development of a 99mTc-HSA prepa-
ration technique using autologous serum elution, the 99mTc-
autoalbumin. In addition to labeling eﬃciency and stability
studies, we performed in vivo biodistribution and biological
half-life studies and tested sterility and pyrogenicity.
2.Materialsand Methods
2.1. Extraction of Albumin from Serum. Fresh serum was
collected following centrifugation (3,500rpm for 5 minutes)
of single-source blood samples from healthy volunteers.
Aﬃnity chromatographic columns, which is cross-linked
agarose gel with covalently coupled Cibacron Blue [17]
(Aurum Aﬃ-Gel Blue column; Bio-Rad catalog no. 732-
6708, CA, USA), were prepared by washing with low-salt
20mM Tris buﬀersolution (pH 8.3) and desiccated in a mic-
rocentrifuge (7,000rpm for 5 seconds). Serum samples were
prepared by dilution with Tris buﬀer solution at 1:3. Serum
sample (800μL) was then added to the column, and the
column was gently vortexed for 5 to 10 minutes. The column
w a sa l l o w e dt od r a i na n dw a s h e dt w i c ew i t hT r i sb u ﬀer
solution. All ﬂow-through was discarded, and the serum
protein remained bound to the column’s resin beads. Two
elution buﬀer solutions were used to remove the protein
fraction from the bead.
Preparation 1 (Pre-1). Laemmli sample buﬀer (Bio-Rad cat-
alog no. 161-0737).
Major content: 62.5mM Tris-HCl (pH: 6.8), 25% glyc-
erol, 2% SDS, and 0.01% Bromophenol blue.
Preparation 1 (Pre-1). Preparation 2(Pre-2):ReadyPrep seq-
uential extraction reagent 3 (Bio-Rad catalog no. 163-2104).
Major content: 5M urea, 2M thiourea, 2% CHAPS, 2%
SB 3–10, 40mM Tris, and 0.2% Bio-Lyte 3/10 ampholyte.
Five hundred microliters of elution buﬀer were added,
a n dt h ec o l u m nw a ss p u nf o r5s e c o n d sa t7 , 0 0 0 r p mi n
a microcentrifuge. The residual elution was collected and
labeled as “serum protein.”
Albumin fraction and amount ofthe serum protein sam-
ples were obtained by cellulose acetate strip electrophoresis.
Brieﬂy,Tris-barbital-sodium barbitalbuﬀersolution(Electra
HR Buﬀer, Helena laboratories catalog no. 5805, TX, US)
was added to the electrophoresis tank (SPIFE 3000, Helena
Laboratories). Serum sample was applied to the plate (Titan
III Cellulose Acetate, Helena laboratories catalog no. 3023)
and electrophoresed at 180V for 25 minutes. After the
electrophoresis was done, the plates were removed from
the electrophoresis chamber and stained (Ponceau S Stain,
Helena Laboratories catalog no. 5526) for 5 minutes. A
scanning densitometer (QuickScan 2000, Helena Labora-
tories) was employed for the estimation of the results of
electrophoresis.
A serum sample without any extraction procedure (Pre-
3) was also examined as an internal control. The preparation
group with the highest albumin fraction was chosen, and the
radiolabeling procedures described below were performed.
2.2. Preparation of the 99mTc-Labeled Autoalbumin. After
proper serum extraction of the albumin, radiolabeling was
initiated. Sodium pertechnetate (99mTc-pertechnetate) was
eluted from an 99Mo/99mTc generator (Ultra-Techne Kow;
Daiichi Radioisotope Laboratories, LTD., Tokyo, Japan), fol-
lowing manufacturer’s instructions. Stannous solution (Am-
erscan Stannous Agent, Amersham plc, Buckinghamshire,
UK) was prepared fresh by careful addition of 10mL 0.9%
sodium chloride to the kit’s vial. The ﬁnal concentration
of the stannous ﬂuoride in the stannous solution was
0.4mg/mL.
Labelingwascarriedoutbymixing autoalbuminwiththe
stannous solution and 99mTc-pertechnetate. Two diﬀerent
preparation protocols of 99mTc-autoalbumin were prepared,
with (Protocol A) and without (Protocol B) stannous solu-
tion. First, 0.5mL autoalbumin was measured and aliquoted
into a sterile tube (BD Vacutainer; Becton, Dickinson and
Company, NJ, US), then the stannous solution (0.5mL)
was added to the Protocol A test tubes using volumetric
pipettes. After 99mTc-pertechnetate elution was completed;
total activity was measured by a dose calibrator (CRC-15R;
Capintec, Inc., NJ, US). 1.11 GBq of 99mTc-pertechnetate
was collected and added with 0.9% sodium chloride to bring
the ﬁnal volume to 0.5mL, and then it was placed in a
sterile tube. The autoalbumin and stannous mixtures were
then transferred aseptically to the tubes containing 99mTc-
pertechnetate using a syringe to carefully deliver the solution
d o w nt h es i d ew a l lo ft h et u b e s .M i x i n gw a sp e r f o r m e db y
gentle manual shaking to avoid bubble formation.
2.3. Radiochemical Purity and Stability. Radiochemical pu-
rity and stability were determined by instant thin-layer
chromatography (ITLC). Initially, ITLC silica gel plate was
cut into 0.8 × 10cm2 strips. Using a Hamilton syringe,
one drop of the specimen was placed at 1.5cm above the
bottom of the strip. The strip was developed by acetone, and
the radioactivity distribution over the strip was determined
with a radio-TLC imaging scanner (AR-2000; Bioscan, Inc.,
Washington, DC, US). Radiochemical purity was calculated
as the fraction of radioactivity that remained at the origin
and was designated as %RCP. After preparation, the stability
of the mixture was acquired from sequential repeats (n = 6)
of the %RCP procedure at 10min, 30min, 1 hour, 2 hours, 4
hours, 6 hours, and 24 hours, respectively.
2.4. Biodistribution. A gamma camera (DST-XLi, General
E l e c t r i cM e d i c a lS y s t e m s ,B u c ,F r a n c e )w a su s e dt ov i e wr a t s
(Wistar strain, male, weighing from 200 to 250gm) that
had been injected, via the tail vein, with 74MBq of 99mTc-
autoalbumin. The rats were anesthetized with an intraperi-
toneal injection of pentobarbital (0.006mg/100gm). The
gamma camera was ﬁtted with a low-energy, high-resolutionJournal of Biomedicine and Biotechnology 3
Table 1: Serum protein components separated by diﬀerent elution buﬀers.
Pre-1 Pre-2 Pre-3 Reference [18]
Total protein (gm/dL) 2.00 ±0.16 3.12 ±0.36 7.26 ± 0.19 6.0–8.4
Electrophoresis (%)
Albumin 77.50 ±2.24 4.36 ±1.15 55.14 ± 4.82 52–68
Globulin α12 .86 ±0.57 2.08 ±0.62 2.34 ± 0.21 4.2–7.2
Globulin α26 .12 ±1.88 87.02 ±2.52 8.36 ± 1.06 6.8–12
Globulin β 7.04 ±1.41 3.40 ±1.03 13.36 ± 1.52 9.3–15
Globulin γ 6.48 ±3.23 3.14 ±1.13 20.80 ± 3.53 13–23
collimator, and the images were processed by a gamma-
camera working station (POWERstation SPX, IBM RS6000,
Vision 5.2.0, General Electric Medical Systems). Each rat was
studied by taking 750 frames of 0.4 seconds, followed by 1
frame of 60 seconds (total study time, ∼6m i n u t e s ) .
In addition to the imaging studies, an examination of
biodistribution changes over time was performed. Rats were
injected via tail vein. The animals (n = 5, each group)
were sacriﬁced by direct decapitation at 5, 10, 30, 60, 120,
and 240min after administration of 99mTc-autoalbumin,
followed by dissection. Organs and tissues were separated,
and the radioactivity was determined using a gamma
counter (COBRAII, Packard, Netherlands). Organ activity
was expressed as a mean of percentage of injected dose per
grams (%ID/gm) of tissue.
2.5. Blood Clearance. Blood clearance studies were per-
formed to understand the in vivo behavior of the injected
99mTc-autoalbumin. Rats (n = 5) without previous admin-
istration of any radiopharmaceutical were acquired. The
radiolabeled preparations were diluted with 0.9% sodium
chloride to a ﬁnal concentration of 74MBq/mL, and 0.2mL
of this preparation was injected into the proximal portion of
the tail vein. At ﬁxed time intervals (5, 10, 15, 30, 60, and
120min), 0.2mL blood samples were withdrawn from the
distal end of the tail vein. All of the samples were counted
in a gamma well counter and were compared with a value
obtained for a standard radiopharmaceutical. The blood
clearance rates were calculated by means of the logarithmic
equation as follows:
%Radioactivity, blood = q × [ln(Time)] +b. (1)
Time: minutes after injection, q: slope, b:i n t e r c e p t .
2.6. Pyrogenicity and Sterility Testing. Pyrogenicity was de-
termined using a bacterial endotoxin test called the limulus
amebocyte lysate (LAL) test. The sensitivity of the LAL
reagent is 0.25 endotoxin units (EU)/mL. According to the
requirement, as speciﬁed in USP32/NF27 [19], the limit
with regard to endotoxin content of the 99mTc-autoalbumin
preparationis 175/VUSPEU/mL ofthe injection, where V is
the maximum recommended dose in milliliters.
The sterility of the 99mTc-autoalbumin preparation was
tested, as stated in USP32/NF27 [20]. One milliliter of our
preparation was added to a test tube containing 15mL
of SCD and TGC medium. The tubes were observed for
turbidity, and results were recorded every day for 14 days. A
negative result was indicated by a clear culture medium (no
turbidity noted) over the 14 days of observation.
2.7. Ethics. This study was approved by the Institutional
Review Board of the Buddhist Dalin Tzu Chi General
Hospital. All the animal experiments were performed in
accordance with the Animal Protection Act of the Council of
Agriculture, and were approved by the Institutional Animal
Care and Use Committee of Dalin Tzu Chi General Hospital.
3.Results
3.1. AutoalbuminFraction of the Elution. Five serum samples
were prepared according to the protocoldescribed aboveand
were arranged into three groups: preparation 1 (Laemmli
sample buﬀer; Pre-1), preparation 2 (ReadyPrep sequential
extraction reagent 3; Pre-2), and preparation 3 (serum
without any extraction; Pre-3). The Pre-3 served as an
internal control forthe electrophoresis analysis, and ourdata
showed evenly distributed protein elements (Table 1) upon
comparison to the reference range [18], with the exception
of a slightly lower fraction than the globulin α1. Both Pre-1
and Pre-2 exhibited diminished total protein concentrations
(2.00gm/dL and 3.12gm/dL, resp.) as compared to Pre-3
(7.62gm/dL), which was caused by inevitable loss from the
extraction procedure. Pre-1 yielded a higher extraction ratio
of the albumin fraction from the serum protein (77.5%) as
compared with Pre-2 (4.36%) and Pre-3 (55.14%) while the
Pre-2 showed a high fraction in the globulin α2 (87.02%)
then Pre-1 (6.12%) and Pre-3 (8.36%) (Table 1). This result
indicated that Pre-1, the extraction serum with Laemmli
sample buﬀer, eﬀectively isolated a higher proportion of
autoalbumin.Alloftheradiolabelingstudieswereperformed
with high-purity autoalbumin from Pre-1.
3.2. Radiochemical Purity and Stability. Protocol A con-
tained 0.5mL autoalbumin, 0.5mL stannous solution, and
1.11GBq of 99mTc-pertechnetate. Protocol B contained
0.5mL autoalbumin with 1.11GBq of 99mTc-pertechnetate.
Figure 1 demonstrates that the radiochemical purity ob-
tainedwithProtocolAwas95.82%at10min andmaintained
the 94.42% out to 6 hours after preparation. Twenty-four
hours after radiolabeling, the average RCP still reached
72.77% (n = 6 ) .P r o t o c o lB ,h o w e v e r ,r e s u l t e di ns u b s t a n -
tially poorer labeling eﬃciency and was deemed unsuitable
for clinical application.4 Journal of Biomedicine and Biotechnology
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Figure 1: (a) Examples of the radiochemical purity studies from Protocol A and Protocol B. Both showed the RCP result of 30min after
radiolabeling.Radiochromatogramswere acquired witha radio-TLC scanner.(b) Radiochemical purity and stabilitytests ofthe preparation
protocols, determined by ITLC and presented as %RCP with mean ± SD (n = 6).
Table 2: In vivo biodistribution of the 99mTc-autoalbumin, expressed as percentage of administered dose per gram of organ (%ID/gm)
(mean values ± s.e.m.).
Time (min) Brain Lung Liver Stomach Spleen Kidney Muscle Bone
50 .14 ±0.09 0.93 ±0.60 1.46 ±0.63 0.43 ±0.23 0.48 ±0.20 2.91 ±0.72 0.19 ±0.10 0.08 ±0.02
10 0.23 ±0.13 1.03 ±0.64 1.27 ±0.25 0.57 ±0.12 0.73 ±0.21 2.44 ±1.10 0.64 ±0.13 0.23 ±0.10
30 0.02 ±0.01 0.09 ±0.02 0.94 ±0.52 0.22 ±0.08 0.30 ±0.12 3.37 ±0.95 0.06 ±0.01 0.05 ±0.01
60 0.01 ±0.01 0.04 ±0.01 0.76 ±0.11 0.07 ±0.01 0.13 ±0.07 3.29 ±0.86 0.12 ±0.03 0.07 ±0.01
120 0.02 ±0.02 0.09 ±0.03 0.70 ±0.24 0.15 ±0.08 0.30 ±0.09 4.48 ±0.39 0.03 ±0.01 0.07 ±0.02
240 0.01 ±0.01 0.05 ±0.02 0.52 ±0.13 0.11 ±0.03 0.52 ±0.17 4.12 ±0.69 0.04 ±0.03 0.05 ±0.02
3.3.Biodistribution. When the 99mTc-autoalbumin,prepared
as Protocol A, was injected intravenously into a rat, the
mainvessels, heart,lung,liver,andkidneyswere immediately
visualized (Figures 2(a) and 2(b)). Results from the animal
biodistribution studies were expressed as percentages of
injected doses per gram and presented in Table 2.F i v e
minutes after initiation of the study, a percentage of the
injected dose of radiolabeled autoalbumin was detected in
the lung (0.93%), liver (1.46%), and kidneys (2.91%). The
distributions to the lung (1.04%) and liver (1.27%) were
highest at 10 minutes after intravenous injection of the
radiotracer. These levels were reduced in lung and liver, butJournal of Biomedicine and Biotechnology 5
1 2345 6
7 8 9 10 11 12
(a) (b)
Figure 2: Image studies for the biodistribution of the 99mTc-autoalbumin. (a) Dynamic images, rats were studied by taking 750 frames of
0.4 seconds interval; (b) static image taken at 5min after injection with an acquisition time of 60 seconds.
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Figure 3: Blood clearance of the 99mTc-autoalbumin in study
animals (n = 5).
in the kidneys gradually increased to 4.48% over the ﬁrst 2
hours. The radiodistribution of the stomach and other inter-
nal organs, such as spleen, showed no apparent diﬀerence
(stomach: 0.57% to 0.11%; spleen: 0.73% to 0.13%).
3.4. Blood Clearance. The serum elimination of this radio-
labeled autoalbumin has been shown in Figure 3.Ad e c l i n e
in percentage of injected dose in blood was observed over
time. The formula used to calculate the blood clearance is
“%Radioactivity = 0.55−0.1×[ln(Time)]”(r2 > 0.95),and
the biological half-life calculated was 32.29 minutes.
3.5. Pyrogenicity and Sterility Testing. After 6 hours, remain-
ing 99mTc-autoalbumin was used to perform pyrogen and
sterility tests (n = 5). In the pyrogenicity tests, those
samples diluted 50-fold and 83-fold (the maximum valid
dilution value) yielded negative results. In addition, after
being incubated for 14 days, our culture medium remained
clear in appearance. All samples were found to be sterile and
pyrogen-free.
4.Discussion
The term autologous transfusion describes any procedure by
which donated blood (or serum component) is transfused
(or reinfused) into the donor/patient [21]. The primary
purpose of autologous transfusion is to prevent exposure to
blood-borne infectious agents. This has become increasingly
critical as awareness of the risks of allergenic blood products
has grown in the decades following the AIDS epidemic that
plagued the late 1980s and early 1990s.
The ﬁrst step of this study was designed to establish
an autoalbumin extraction procedure from single-source,
autologous serum. Speciﬁcally, the serum sample was placed
in a resin bead column to capture the protein component.
Upon release from the column, total protein and separated
component fractions were examined by electrophoresis. An
internal control sample provided the reference range of
serum protein distribution, with the exception of a relatively
lowerfraction oftheglobulinα1. ElutionbyLaemmli sample
buﬀer yielded a high albumin elution fraction (77.5%) while
elution by ReadyPrep sequential extraction reagent 3 yielded
a higher fraction in the globulin α2. Serum samples subject
to resin bead column isolation and elution by Laemmli
sample buﬀer were determined to be suitable for use with
the subsequent radiolabeling procedure.
Radiolabeling was performed by carefully mixing 99mTc-
pertechnetate and autoalbumin. Stannous is essential for
good radiolabeling eﬃciency. Our data showed that the ra-
diochemical purity and stability were suﬃcient, because 6
hours after radiolabeling, the %RCP still reached more than
94%.Whentheradiolabeled autoalbuminwasinjected intra-
venouslyintoarat,thelung,liver,andkidneyswerepromptly
visualized. The distribution to the lung and liver was highest
within the initial 10 minutes and then vanished gradually.
In the kidney, the accumulation of radioactivity became
progressively prominent, suggesting the major excretory
pathway of radiolabeled autoalbumin may be the genitouri-
narytract.The radioactivitytothegastric mucosashowed no6 Journal of Biomedicine and Biotechnology
signiﬁcant diﬀerence as other internal organs, for example,
spleen, could be an in vivo demonstration of stable labeling
of Technetium-99m and autoalbumin in study animals.
A previous literature report of the biodistribution in
rat with 99mTc-HSA demonstrates a rapid accumulation of
tracer to the liver immediately after injection while the time-
activity cure showed slightly decreased radio-uptake with
time [22]. Excretion of tracer through the kidneys could be
also identiﬁed right after injection of tracer. Another study
described the biodistribution of the recombinant human
serum albumin (rHSA) also showed major initial distribu-
tion to the liver [23]. However, progressive decrement of
liver uptake and increment of renal activity were also ob-
served. In this study, time series sacriﬁces and dissection of
organs/tissues were performed. Our results were consistent
with these reports for the biodistribution study.
Autologous blood and blood components are widely
believed to be the safest blood products available for clinical
application; however, certain complications are still possible
and should be kept under a strict watch. Contamination
by bacteria or other pyrogens during the preparation steps
remain a risk. Our autoalbumin preparation procedure was
determined to be free from pyrogenicity and passed sterility
tests; however, operator errors or negligence may still occur.
Prevention of contamination is of ultimate importance in
clinical practice of nuclear medicine. Another operator error
that may occur is mislabeling of serum tubes. This mistake
yields the identical risks associated with nonautologous
transfusion and can lead to serum product administration
to an incompatible patient.
Autologouspreparationsofbloodcomponenttechniques
aregenerallyintendedtoreplaceasmuchoftheallogenicori-
gin as possible by reinfusion of autologous blood products.
Our study demonstrates that the separation of autoalbumin
takes no longer than 2 hours and radiolabeling may be
carried out immediately after separation. This implies that
the collection and reprocessing of radiolabeled autoalbumin
and the subsequent nuclear medical procedure could be
performed as a daily practice. Even though 99mTc-albumin
labeling has demonstrated some clinical advantages, it is still
a signiﬁcantly hazardous procedure. Therefore, it may not be
worth the risk if a kit formulation is available to be used.
The most recent development of nonserum sources of
human albumin has been the rHSA [23–26]. Both rHSA
a n dp H S Ah a v eb e e ns h o w nt ob ei d e n t i c a li ns t r u c t u r ea n d
physiochemical and immunochemical properties [27, 28]. In
the future, rHSA promises to be an ideal source for a “clean”
HSA.
5.Conclusions
Radiolabeled human serum albumin is an important nuclear
medicine radiopharmaceutical. However, the safety of pool-
ed serum products remains a concern. Our study demo-
nstrates that autoalbumin can be eﬃciently extracted within
anuclearmedicinelaboratoryand immediatelyradiolabeled.
This radiolabeled autoalbumin exhibited suﬃcient radio-
chemical purity and stability. The most important advantage
to this technique is that the risk of infection could be sig-
niﬁcantly eliminated by this preparation of autoalbumin.
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